The receptor pharmacology is classical: GLP-1R binding on pancreatic beta cells and extra-pancreatic tissues including CNS, stomach, and cardiovascular tissues, with Gs-adenylyl cyclase-PKA downstream signaling
GLP-1 Market Size, Share & Trends Analysis Report By Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist), By Type of Agonist (Single Agonist, Dual Agonist, Tri-agonist), By Molecule Type (Biologic Peptide GLP-1 Agonists, Small-Molecule Non-Peptide GLP-1 Agonists), By Active Compound (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide, Lixisenatide, Exenatide, Orforglipron, Retatrutide, Survodutide, Other Active Compounds), By Route of Administration (Oral, Parenteral), By Dosing Frequency (Daily, Weekly, Monthly or Extended-Interval), By Delivery System, By Target Indication, By Payer, By Region and By Segments Forecasts, 2026 to 2035
Among these, semaglutide has demonstrated reduced risk of major adverse cardiovascular events (MACE) in trial participants with moderate or high cardiovascular risk
Choosing the best time to take GLP-1 depends on your lifestyle, side effect tolerance, and blood sugar patterns
GLP-1 agonists were originally designed to treat Type 2 diabetes
Its a semaglutide medication formulated for your individual needs